Phase I clinical trial of immunotherapy with WT1 peptide vaccine for hematological malignancies after stem cell transplantation

Phase I clinical trial of immunotherapy with WT1 peptide vaccine for hematological malignancies after stem cell transplantation - Phase I clinical trial of immunotherapy with WT1 peptide vaccine for hematological malignancies after stem cell transplantation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004753

Enrollment

Registered

2010-12-21

Start date

2010-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myeloid or lymphoid leukemia malignant lymphoma multiple myeloma

Interventions

Modified WT1 peptide (235-243) with montanide ISA51 is subcutaneously injected weekly for a month.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: see Japanese protocol or ask directly to us

Exclusion criteria

Exclusion criteria: see Japanese protocol or ask directly to us

Design outcomes

Primary

Measure	Time frame
Adverse events	—

Countries

Japan

Contacts

Public ContactNaoki Hosen

Osaka University Cancer Immunmotherapy

hnaoki@imed3.med.osaka-u.ac.jp06-6879-3676

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026